What is the differential diagnosis, workup, and management for a female patient with elevated red blood cell count (5.77 million/µL), hemoglobin (17.2 g/dL), and hematocrit (52.6 %)?

Evaluation and Management of Erythrocytosis in a Female Patient

This female patient meets WHO diagnostic criteria for polycythemia vera (PV) and requires immediate workup including JAK2 mutation testing, serum erythropoietin level, and bone marrow biopsy to confirm the diagnosis. 1, 2, 3

Diagnostic Approach

Initial Assessment

The patient's values significantly exceed diagnostic thresholds for PV in women:

• Hemoglobin 17.2 g/dL (WHO criterion: >16.5 g/dL for women) 1, 2, 3
• Hematocrit 52.6% (WHO criterion: >48% for women) 4
• RBC count 5.77 million/µL (elevated)

These values fulfill the first major criterion for PV diagnosis according to 2016 WHO classification 4.

Differential Diagnosis Priority

Primary (Clonal) Causes:

• Polycythemia vera - most likely given the degree of elevation 1, 2
• Essential thrombocythemia with erythrocytosis
• Primary myelofibrosis (early/pre-fibrotic)

Secondary Causes to Exclude:

• Chronic hypoxemia (lung disease, sleep apnea, high altitude, cyanotic heart disease) 5
• Erythropoietin-secreting tumors (renal cell carcinoma, hepatocellular carcinoma, uterine leiomyoma)
• Exogenous erythropoietin or androgen use
• SGLT2 inhibitor use 6

Other Considerations:

• Relative polycythemia (plasma volume contraction/dehydration) 7, 6
• Hereditary erythrocytosis (high-affinity hemoglobin variants, VHL mutations) 8, 9

Mandatory Initial Workup

Step 1: Confirm True Erythrocytosis

• Repeat complete blood count with differential
• Assess for dehydration, diuretic use
• Check platelet count and white blood cell count (if elevated, strongly suggests MPN) 10, 11

Step 2: Test for Clonal Disease (perform simultaneously)

• JAK2 V617F mutation - present in >95% of PV cases 1, 2
• Serum erythropoietin level - low or low-normal in PV (>90% specificity), elevated in secondary causes 10
• If JAK2 V617F negative: test for JAK2 exon 12 mutations 1, 2, 3

Step 3: Exclude Secondary Causes

• Oxygen saturation measurement
• Chest X-ray or CT if hypoxemia suspected
• Renal and liver imaging (ultrasound) to exclude tumors
• Medication review (androgens, erythropoietin, SGLT2 inhibitors)
• Smoking history 1

Step 4: Bone Marrow Biopsy (if JAK2 positive or EPO low)

• Required to meet WHO diagnostic criteria 1, 2, 4
• Look for hypercellularity with trilineage myeloproliferation (panmyelosis)
• Assess for pleomorphic megakaryocytes
• Exclude myelofibrosis (reticulin grade)
• Cytogenetic studies 10

WHO 2016 Diagnostic Criteria for PV

Diagnosis requires:

• Both major criteria + one minor criterion, OR
• First major criterion + two minor criteria 1, 4

Major Criteria:

1. Hemoglobin >16.5 g/dL (women) or Hematocrit >48% (women) ✓ Patient meets this
2. Bone marrow showing hypercellularity with trilineage growth
3. Presence of JAK2 V617F or JAK2 exon 12 mutation

Minor Criteria:

1. Subnormal serum erythropoietin level
2. Endogenous erythroid colony formation in vitro

Critical Pitfalls to Avoid

Iron Deficiency Masking: PV patients may have normal or even low hemoglobin if iron deficient from chronic phlebotomy or occult bleeding 10, 12. Check ferritin, transferrin saturation, and peripheral smear for microcytosis. This patient's elevated values despite potential iron deficiency would make PV even more likely 12.

Do NOT perform routine phlebotomy before confirming diagnosis, as this can deplete iron stores and complicate interpretation 5.

Avoid assuming secondary causes without testing for JAK2 mutations first when values are this elevated in the absence of obvious hypoxemia 6.

Management if PV Confirmed

Risk Stratification

• High-risk: Age >60 years OR history of thrombosis
• Low-risk: Age ≤60 years AND no thrombosis history 1, 11

Treatment Algorithm

All Patients:

• Phlebotomy to maintain hematocrit <45% (Class I recommendation) 1, 11
• Low-dose aspirin 81-100 mg daily (unless contraindicated) 1, 11
• Aggressive management of cardiovascular risk factors 1

High-Risk Patients (add cytoreductive therapy):

• First-line: Hydroxyurea 1, 11
• Alternative: Interferon alfa-2b or peginterferon alfa-2a/2b (preferred in younger patients, pregnancy) 1, 11

Monitoring:

• Regular CBC monitoring
• Assess for thrombotic/hemorrhagic complications
• Monitor for disease progression to myelofibrosis or acute leukemia 1

Therapeutic Phlebotomy Guidelines

Indications for urgent phlebotomy:

• Hemoglobin >20 g/dL AND hematocrit >65% with hyperviscosity symptoms (headache, fatigue, visual disturbances) 5
• Always replace volume with equal amount of saline or dextrose 5

Avoid repeated routine phlebotomies without volume replacement due to risk of iron depletion, decreased oxygen-carrying capacity, and stroke 5.

If Secondary Erythrocytosis Confirmed

Management depends on underlying cause:

• Treat hypoxemia (supplemental oxygen, CPAP for sleep apnea)
• Remove causative medications
• Surgical resection of erythropoietin-secreting tumors
• Phlebotomy only if symptomatic hyperviscosity (no clear hematocrit target; individualize based on symptoms) 6